Larvol Delta - MultiOmicsBased-Phase--Trial-of-Trastuzumab-Rezetecan-Plus-Camrelizumab-for-Perioperative-Therapy-in-HER2Positive-MuscleInvasive-Urothelial-Carcinoma

trastuzumab rezetecan (SHR-A1811) - Jiangsu Hengrui Pharma

Herceptin (trastuzumab) - Roche

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://clinicaltrials.gov/ct2/show/NCT07639983

Jun 11, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next